- Home
- IMMX vs IFRX Comparison
IMMX vs IFRX Comparison
Compare IMMX & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- IFRX
- Stock Information
- Founded
- IMMX 2014
- IFRX 2007
- Country
- IMMX United States
- IFRX Germany
- Employees
- IMMX N/A
- IFRX N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- IFRX Health Care
- Exchange
- IMMX Nasdaq
- IFRX Nasdaq
- Market Cap
- IMMX 65.5M
- IFRX 53.5M
- IPO Year
- IMMX 2021
- IFRX 2017
- Fundamental
- Price
- IMMX $2.00
- IFRX $1.14
- Analyst Decision
- IMMX Strong Buy
- IFRX Strong Buy
- Analyst Count
- IMMX 1
- IFRX 5
- Target Price
- IMMX $8.00
- IFRX $7.40
- AVG Volume (30 Days)
- IMMX 183.0K
- IFRX 1.0M
- Earning Date
- IMMX 11-11-2025
- IFRX 11-07-2025
- Dividend Yield
- IMMX N/A
- IFRX N/A
- EPS Growth
- IMMX N/A
- IFRX N/A
- EPS
- IMMX N/A
- IFRX N/A
- Revenue
- IMMX N/A
- IFRX $191,224.00
- Revenue This Year
- IMMX N/A
- IFRX N/A
- Revenue Next Year
- IMMX N/A
- IFRX $1,216.24
- P/E Ratio
- IMMX N/A
- IFRX N/A
- Revenue Growth
- IMMX N/A
- IFRX 54.36
- 52 Week Low
- IMMX $1.26
- IFRX $0.71
- 52 Week High
- IMMX $3.20
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- IMMX 48.92
- IFRX 45.40
- Support Level
- IMMX N/A
- IFRX $1.45
- Resistance Level
- IMMX $2.34
- IFRX $1.77
- Average True Range (ATR)
- IMMX 0.15
- IFRX 0.21
- MACD
- IMMX -0.08
- IFRX -0.04
- Stochastic Oscillator
- IMMX 85.11
- IFRX 24.94
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.